| Dr Fulvia Carmen Banu, MD | |
|
1724 E Hallandale Beach Blvd # 2a, Hallandale Beach, FL 33009-4611 | |
| (954) 456-9696 | |
| (954) 456-9626 |
| Full Name | Dr Fulvia Carmen Banu |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 31 Years |
| Location | 1724 E Hallandale Beach Blvd # 2a, Hallandale Beach, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073908752 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | ME134115 (Florida) | Primary |
| Entity Name | Criticare Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508871948 PECOS PAC ID: 7517966534 Enrollment ID: O20061220000143 |
News Archive
Patients with a condition that causes blood vessels in the brain to form an abnormal tangle could be helped by the findings of new research.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
A leading Australian expert has warned that the international attention devoted to HIV/AIDS has dwarfed the threat of tuberculosis (TB).
Biotechnology company Arana Therapeutics Limited today announced it has submitted an Investigational New Drug application (IND) to the FDA (U.S. Food and Drug Administration) for the anti-inflammatory product ART621 in a rheumatoid arthritis (RA) indication.
› Verified 2 days ago
| Entity Name | Banu Medical Practice Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063155570 PECOS PAC ID: 4981091444 Enrollment ID: O20220502000909 |
News Archive
Patients with a condition that causes blood vessels in the brain to form an abnormal tangle could be helped by the findings of new research.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
A leading Australian expert has warned that the international attention devoted to HIV/AIDS has dwarfed the threat of tuberculosis (TB).
Biotechnology company Arana Therapeutics Limited today announced it has submitted an Investigational New Drug application (IND) to the FDA (U.S. Food and Drug Administration) for the anti-inflammatory product ART621 in a rheumatoid arthritis (RA) indication.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Fulvia Carmen Banu, MD 3241 Executive Way, Miramar, FL 33025-3931 Ph: (954) 985-6500 | Dr Fulvia Carmen Banu, MD 1724 E Hallandale Beach Blvd # 2a, Hallandale Beach, FL 33009-4611 Ph: (954) 456-9696 |
News Archive
Patients with a condition that causes blood vessels in the brain to form an abnormal tangle could be helped by the findings of new research.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
A leading Australian expert has warned that the international attention devoted to HIV/AIDS has dwarfed the threat of tuberculosis (TB).
Biotechnology company Arana Therapeutics Limited today announced it has submitted an Investigational New Drug application (IND) to the FDA (U.S. Food and Drug Administration) for the anti-inflammatory product ART621 in a rheumatoid arthritis (RA) indication.
› Verified 2 days ago
Dr. Benjamin Lechner, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 2100 E Hallandale Beach Blvd, Suite 302, Hallandale Beach, FL 33009 Phone: 954-456-8900 Fax: 954-457-9118 | |
Abdur Rahman Baig, M.D. Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 2500 E Hallandale Beach Blvd, Suite 207, Hallandale Beach, FL 33009 Phone: 954-800-0953 | |
Katharina Castro, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 410 E Hallandale Beach Blvd, Hallandale Beach, FL 33009 Phone: 305-827-2977 Fax: 305-692-0717 | |
Grace Maher Reynolds, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1849 South Ocean Dr. Pts 911, Hallandale Beach, FL 33009 Phone: 954-457-2744 Fax: 954-457-2744 | |
Yuriy Pasisnichenko, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3180 S Ocean Dr Apt 1020, Hallandale Beach, FL 33009 Phone: 718-250-6604 | |
Mark Ramsey, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1117 E Hallandale Beach Blvd, Hallandale Beach, FL 33009 Phone: 954-454-6300 |